| Field | Value |
|-------|-------|
| NCT Number | NCT07157735 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Olatec Therapeutics |
| Intervention | Dapansutrile (OLT1177) |
| Mechanism | NLRP3 inflammasome inhibitor |
| Route | Oral |
| Study Design | Randomized, double-blind, placebo-controlled |
Parkinson's disease (PD) is the second most common neurodegenerative disorder, affecting approximately 10 million people worldwide[@kalia2015]. The disease is characterized by progressive loss of dopaminergic neurons in the substantia nigra pars compacta, leading to the hallmark motor symptoms including bradykinesia, resting tremor, rigidity, and postural instability. Additionally, non-motor symptoms such as cognitive impairment, depression, sleep disorders, and autonomic dysfunction significantly impact quality of life[@bloem2021].
Despite decades of research, current treatments remain primarily symptomatic, focusing on dopamine replacement therapy with levodopa and dopamine agonists. While these interventions provide substantial benefit, they do not halt or slow disease progression. The development of disease-modifying therapies remains an urgent unmet need[@jankovic2020].
| Field | Value |
|-------|-------|
| NCT Number | NCT07157735 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Olatec Therapeutics |
| Intervention | Dapansutrile (OLT1177) |
| Mechanism | NLRP3 inflammasome inhibitor |
| Route | Oral |
| Study Design | Randomized, double-blind, placebo-controlled |
Parkinson's disease (PD) is the second most common neurodegenerative disorder, affecting approximately 10 million people worldwide[@kalia2015]. The disease is characterized by progressive loss of dopaminergic neurons in the substantia nigra pars compacta, leading to the hallmark motor symptoms including bradykinesia, resting tremor, rigidity, and postural instability. Additionally, non-motor symptoms such as cognitive impairment, depression, sleep disorders, and autonomic dysfunction significantly impact quality of life[@bloem2021].
Despite decades of research, current treatments remain primarily symptomatic, focusing on dopamine replacement therapy with levodopa and dopamine agonists. While these interventions provide substantial benefit, they do not halt or slow disease progression. The development of disease-modifying therapies remains an urgent unmet need[@jankovic2020].
Neuroinflammation has emerged as a critical driver of PD pathogenesis. The NLRP3 (NLR Family Pyrin Domain Containing 3) inflammasome plays a central role in chronic neuroinflammation observed in Parkinson's disease. This intracellular protein complex activates caspase-1, leading to the production of pro-inflammatory cytokines interleukin-1β (IL-1β) and interleukin-18 (IL-18), as well as the initiation of pyroptosis, a form of inflammatory cell death[@zhou2021].
In PD, microglial NLRP3 is chronically activated by α-synuclein aggregates, mitochondrial dysfunction, and environmental toxins. This activation creates a self-perpetuating cycle of neuroinflammation that drives dopaminergic neuron loss. Studies have demonstrated elevated NLRP3 activation and increased IL-1β levels in the substantia nigra and cerebrospinal fluid of PD patients[@haque2019].
Dapansutrile (also known as OLT1177) is a novel, selective NLRP3 inflammasome inhibitor developed by Olatec Therapeutics. Unlike broad-spectrum anti-inflammatory drugs, dapansutrile offers targeted inhibition of this specific inflammatory pathway[@marchetti2018].
The molecular mechanism involves:
Dapansutrile has demonstrated favorable pharmacological properties in preclinical and clinical studies:
The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model is a well-established preclinical model of PD. Studies with dapansutrile have demonstrated significant neuroprotective effects[@liang2020]:
The 6-hydroxydopamine (6-OHDA) model provides complementary evidence for dapansutrile's neuroprotective effects[@yan2020]:
Preclinical studies have established that dapansutrile's neuroprotective effects are mediated through NLRP3 inhibition[@greaney2022]:
Dapansutrile has undergone extensive Phase 1 evaluation demonstrating:
Prior to the PD trial, dapansutrile has been evaluated in Phase 2 trials for various inflammatory conditions including:
The Phase 2 clinical trial represents a critical milestone for dapansutrile in PD:
The NLRP3 inflammasome plays a critical role in chronic neuroinflammation observed in Parkinson's disease. In PD[@zhou2021][@greaney2022]:
Dapansutrile's anti-inflammatory mechanism directly targets this fundamental inflammatory pathway, offering the potential for disease modification rather than merely symptomatic relief.
Clinical studies have demonstrated elevated inflammatory markers in PD patients:
The trial enrolls patients meeting criteria for Parkinson's disease diagnosis:
Primary Outcomes:
Based on preclinical data, dapansutrile may provide:
Potential risks include:
For more detailed information, see related pages:
The Phase 2 trial of dapansutrile (NCT07157735) represents an important step toward developing disease-modifying therapies for Parkinson's disease. By targeting the NLRP3 inflammasome, a central mechanism of neuroinflammation, dapansutrile offers a novel approach that addresses the underlying pathophysiology of PD rather than merely alleviating symptoms.
The strong preclinical evidence demonstrating neuroprotection in multiple PD models, combined with the established safety profile from prior clinical trials, provides a solid foundation for this clinical investigation. Successful results would represent a significant advance in the treatment of Parkinson's disease and validate NLRP3 as a therapeutic target in neurodegeneration.
The NLRP3 inflammasome has attracted significant attention as a therapeutic target, leading to the development of multiple inhibitors[@zhang2023]. Understanding how dapansutrile compares with other candidates provides context for its clinical potential.
MCC950 was the most extensively studied preclinical NLRP3 inhibitor, demonstrating potent neuroprotection in PD models. However, clinical development was discontinued due to hepatotoxicity observed in Phase 1 trials. This safety concern highlighted the challenges of targeting NLRP3 systemically while maintaining an acceptable therapeutic window.
Inzomelid is another NLRP3 inhibitor that has entered clinical trials for inflammatory conditions. Like dapansutrile, it offers selective NLRP3 inhibition with a favorable safety profile. However, inzomelid has not yet been evaluated in PD clinical trials.
Dapansutrile offers several advantages for PD treatment:
Beyond Parkinson's disease, dapansutrile holds promise for other neurodegenerative disorders characterized by neuroinflammation. Multiple System Atrophy (MSA) shares pathological features with PD, including α-synuclein aggregation and neuroinflammation. Preclinical studies have demonstrated dapansutrile's efficacy in MSA models[@mechanisms/nlrp3-inflammasome].
The NLRP3 inflammasome also plays a role in Alzheimer's disease pathophysiology. Dapansutrile has demonstrated benefits in AD mouse models, reducing amyloid pathology and improving cognitive function. Future clinical trials in AD may be considered based on PD trial results.
ALS involves neuroinflammation as a component of disease pathogenesis. NLRP3 inhibition represents a potential therapeutic strategy, and dapansutrile's safety profile makes it a candidate for future ALS investigations.
Given the significant unmet need in Parkinson's disease and the novel mechanism of action, dapansutrile may qualify for orphan drug designation in certain jurisdictions. This status could provide regulatory incentives and accelerated approval pathways.
Modern clinical trial designs allow for adaptive approaches that can optimize resource utilization and increase the likelihood of detecting efficacy signals. The NCT07157735 trial may incorporate adaptive elements such as sample size re-estimation or dose selection based on interim analyses.
The identification and validation of NLRP3-related biomarkers represents an important development pathway. Potential biomarkers include:
Parkinson's disease imposes substantial economic burden on patients, families, and healthcare systems. Direct medical costs include medications, hospitalizations, and long-term care. Indirect costs arise from reduced productivity and caregiver burden. Disease-modifying therapies that slow progression could significantly reduce these economic impacts.
Current PD management requires escalating healthcare resources as disease advances. Dopaminergic medications, deep brain stimulation, and institutional care represent significant costs. Successful neuroprotective therapy could reduce or delay these resource needs.
Beyond economic considerations, PD severely impacts patient quality of life. Motor disabilities limit independence, while non-motor symptoms contribute to depression, anxiety, and cognitive decline. Disease-modifying treatment would address these fundamental limitations of current therapy.
Several questions remain regarding optimal patient selection for NLRP3 inhibitor therapy:
While preclinical data strongly support NLRP3 as a therapeutic target, human validation remains incomplete:
The long-term effects of NLRP3 inhibition require investigation:
The Phase 2 clinical trial of dapansutrile (NCT07157735) represents a pivotal moment in the development of NLRP3-targeted therapies for neurodegenerative diseases. This innovative approach addresses the fundamental inflammatory mechanisms that contribute to Parkinson's disease progression, offering potential for disease modification rather than purely symptomatic relief.
The strong scientific foundation supporting this trial includes:
Successful completion of this trial would not only validate dapansutrile as an effective PD therapy but also establish NLRP3 inhibition as a viable therapeutic strategy for neurodegeneration more broadly. This could catalyze further development of next-generation NLRP3 inhibitors and combination approaches targeting multiple pathological mechanisms.
The journey from preclinical discovery to clinical validation exemplifies the challenges and opportunities in neurodegenerative disease drug development. While significant obstacles remain, the dapansutrile Phase 2 trial represents meaningful progress toward addressing one of medicine's most challenging therapeutic areas. Created: 2026-03-27 Last updated: 2026-03-27